Lindynette (Ethinylestradiol, Gestodene)

Lindynette, a combined oral contraceptive, is used to prevent pregnancy by modulating the hormonal regulation of the menstrual cycle.

• Prevention of pregnancy: provides reliable contraceptive protection for women of childbearing potential.
• Cycle regulation: helps achieve more predictable menstrual bleeding patterns and may reduce dysmenorrhea.
• Management of ovarian cysts: can suppress the development of functional ovarian cysts in women with recurrent cyst formation.

• Lindynette combines ethinylestradiol, a synthetic estrogen, with gestodene, a progestogen. The estrogen component suppresses follicle‑stimulating hormone (FSH) release, while the progestogen inhibits luteinising hormone (LH) surge, together preventing ovulation. Additionally, the progestogen thickens cervical mucus and the estrogen‑progestogen mix induces endometrial alterations that reduce the likelihood of implantation.

Lindynette may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset, often transient.
• Breast tenderness: discomfort or swelling of breast tissue.
• Headache: occasional tension‑type or migraine‑like pain.
• Breakthrough bleeding: spotting between periods, especially during early cycles.
• Weight fluctuation: mild fluid retention or appetite changes.
• Mood changes: irritability or mild depressive symptoms.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism, requiring immediate medical attention.
• Arterial thrombosis: stroke or myocardial infarction, particularly in high‑risk individuals.
• Severe hypertension: sudden increase in blood pressure that may be life‑threatening.
• Hepatic adenoma: benign liver tumor associated with prolonged estrogen exposure.
• Anaphylaxis: rare severe allergic reaction with rash, swelling, and respiratory distress.
• Visual disturbances: sudden loss of vision or eye pain, indicating possible vascular events.

Before prescribing Lindynette, clinicians should evaluate individual risk factors and contraindications.

• Pregnancy contraindication: do not use in women who are or may become pregnant.
• Smoking restriction: avoid in women over 35 who smoke more than 15 cigarettes per day.
• Thromboembolic history: contraindicated in patients with past deep vein thrombosis, pulmonary embolism, or stroke.
• Liver disease: avoid in active liver disease or hepatic tumors.
• Hypertension: monitor and control blood pressure before initiating therapy.
• Store at ambient temperature: keep tablets in the original packaging, protect from moisture and direct sunlight.

Lindynette can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Enzyme inducers (e.g., rifampicin, phenytoin, carbamazepine): may reduce contraceptive efficacy.
• Antifungal agents (e.g., ketoconazole, itraconazole): can increase hormone levels and risk of side effects.
• HIV protease inhibitors (e.g., ritonavir): may affect hormone metabolism.

Moderate Interactions (Monitor Closely)

• Selective serotonin reuptake inhibitors (SSRIs): may slightly increase plasma hormone concentrations.
• Antihypertensive drugs: combined use may require blood pressure monitoring.
• Antidiabetic agents: hormonal changes can affect glucose control, necessitating dose adjustments.